Non-Small Cell Lung Cancer Study
Principal Investigator: Addison R. Tolentino, MD
Sub-Investigators: Mark R. Huber, MD; Amy K. Krie, MD; Michael Robinson, MD
Study Coordinator: Erika Meyer, RN
Study Description: A Phase 3, Multi-Center, Randomized, Placeo-Controlled, Double-Blind Trial of AMG 706 in Combination with Paclitaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer
Overview: The purpose of this clinical drug study is to determine the effectiveness and tolerability of an investigational medication used in combination with paclitaxel and carboplatin in treating individuals with advanced non-small cell lung cancer (NSCLC).
Participants in this study will receive a standard paclitaxel and carboplatin chemotherapy regimen, plus either the investigational medication or placebo. In addition, participants will receive the following: physical examination, laboratory evaluations, vital signs measurements, EKG and radiological assessments.
Inclusion Criteria:
- Men and women, age 18 and older
- Histologically-confirmed, unresectable stage IIIB with pericardial or pleural effusion or stage IV or recurrent NSCLC
- Ability to take oral medications
Exclusion Criteria:
- Untreated or symptomatic central nervous system metastases
- Prior chemotherapy for advanced NSCLC; prior adjuvant chemotherapy for NSCLC within 52 weeks; or prior chemoradiation for locally advanced stage III disease
- Central (chest) radiation therapy within 28 days or radiation therapy within 14 days for peripheral lesions
- History of arterial or venous thrombosis within the past 12 months
Contact: Erika Meyer, RN
Phone: (605) 322-3086
Email: erika.meyer@avera.org
Click here to learn more about the Avera Cancer Institute.
